본문 바로가기
HOME> 논문 > 논문 검색상세

논문 상세정보

Japanese journal of clinical oncology v.47 no.1, 2017년, pp.12 - 17   SCIE
본 등재정보는 저널의 등재정보를 참고하여 보여주는 베타서비스로 정확한 논문의 등재여부는 등재기관에 확인하시기 바랍니다.

Efficacy of reduced dose of pegfilgrastim in Japanese breast cancer patients receiving dose-dense doxorubicin and cyclophosphamide therapy

Mizuno, Yoshio (Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003 ) ; Fuchikami, Hiromi (Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003 ) ; Takeda, Naoko (Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003 ) ; Iwai, Masaru (Department of Pharmacy, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003 ) ; Sato, Kazuhiko (Department of Breast Oncology, Tokyo-West Tokushukai Hospital, Akishima, Tokyo 196-0003 ) ;
  • 초록  

    The results from our retrospective study of Japanese breast cancer patients indicate the efficacy of a 3.6-mg pegfilgrastim dose for the primary prevention of febrile neutropenia related to dose-dense chemotherapy. Background This retrospective study aimed to evaluate the efficacy of a 3.6-mg dose of pegfilgrastim for primary prophylaxis in Japanese breast cancer patients receiving dose-dense chemotherapy. Methods Patients treated with adjuvant or neoadjuvant chemotherapy for early-stage breast cancer at the Tokyo-West Tokushukai Hospital were included in this analysis. Because 6 mg pegfilgrastim has not yet been approved for use in Japan, we compared the outcomes of a dose-dense doxorubicin and cyclophosphamide regimen plus 3.6 mg pegfilgrastim support with a conventional dose epirubicin and cyclophosphamide regimen. The incidence of febrile neutropenia, relative dose intensity, dose delay, dose reduction, regimen change and hospitalization because of neutropenia were assessed. Results From November 2013 to March 2016, 97 patients with stage I–III invasive breast cancer were analyzed (dose-dense doxorubicin and cyclophosphamide plus 3.6-mg pegfilgrastim group, n  =  41; epirubicin and cyclophosphamide group, n  =  56; median ages, 49.0 and 48.5 years, respectively). Febrile neutropenia occurred during the first chemotherapy cycle in 7 of 56 patients (12.5%) in the epirubicin and cyclophosphamide group and 0 of 41 patients in the dose-dense doxorubicin and cyclophosphamide group ( P   =  0.02). The average relative dose intensities were 97.9% and 96.8%, respectively ( P   =  0.28), with corresponding dose delay rates of 4.9% (2/41) and 16.1% (9/56), respectively ( P   =  0.11) and dose reduction rates of 0% (0/41) and 7.1% (4/56), respectively ( P   =  0.16). Conclusions Our results indicate the efficacy of a 3.6-mg pegfilgrastim dose for the primary prevention of febrile neutropenia in dose-dense doxorubicin- and cyclophosphamide-treated Japanese breast cancer patients.


  • 주제어

    breast cancer .   doxorubicin .   cyclophosphamide .   pegfilgrastim.  

 활용도 분석

  • 상세보기

    amChart 영역
  • 원문보기

    amChart 영역

원문보기

무료다운로드
  • 원문이 없습니다.
유료다운로드

유료 다운로드의 경우 해당 사이트의 정책에 따라 신규 회원가입, 로그인, 유료 구매 등이 필요할 수 있습니다. 해당 사이트에서 발생하는 귀하의 모든 정보활동은 NDSL의 서비스 정책과 무관합니다.

원문복사신청을 하시면, 일부 해외 인쇄학술지의 경우 외국학술지지원센터(FRIC)에서
무료 원문복사 서비스를 제공합니다.

NDSL에서는 해당 원문을 복사서비스하고 있습니다. 위의 원문복사신청 또는 장바구니 담기를 통하여 원문복사서비스 이용이 가능합니다.

이 논문과 함께 출판된 논문 + 더보기